Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous CAR-T cells B4T2-001

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for an as of yet undisclosed tumor-associated antigen (TAA), with potential immunostimulating and antineoplastic activities. Upon administration, autologous CAR-T cells B4T2-001 target and bind to the TAA-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against the tumor cells, the release of cytotoxic molecules and the induction of tumor cell lysis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	B4t2 001 B4t2-001 B4t2001

autologous CAR-T cells B4T2-001

Search NCI's Drug Dictionary